GSK126, a highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, was also reported to show therapeutic effects in experimental and clinical settings including lymphoma with EZH2-activating mutations 17 and atrial fibrosis 18. Here, EZH2 is linked to lymphoma.